Research funder · United States
Alzheimer's Drug Discovery Foundation
Nonprofit organization
- Grants since 2016
- 326
- Awarded, last 5 years (where amounts are published)
- $245.1M
- Funded works, last 5 years
- 1 178
- Funded works, all time
- 2 272
Grants
2019–2022 · research · Clinical
SHINE (Study Synaptic Health and Improvement of Neurological Function with Elayta): A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
Susan Catalano · Cognition Therapeutics, Inc.
2019–2021 · research · Prevention
Effects of Early Menopausal Hormone Therapy on Imaging Biomarkers of Cognitive Health
Kejal Kantarci · Mayo Clinic
2019–2021 · research · Diagnostics Accelerator
Circulating brain-enriched microRNAs as peripheral biomarkers of neurodegeneration.
Samuil Umansky · Diamir Biosciences
2019–2023 · research · Biomarkers
Cerebrospinal fluid Lipocalin 2 as a specific marker of vascular dementia
Miguel Medina · Ciberned-cnb-csic
2019–2025 · research · Prevention
Effect of early supplementation with high dose DHA on cognitive outcomes in APOE4 carriers: "PreventE4 Trial"
Hussein Yassine · University of Southern California
2019–2025 · research · Clinical
A Phase IIa Trial to Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of TW001 in Alzheimer Patients
Ronald Van Der Geest · Treeway B.v.
2019 · conference · Conferences/Other
1st Workshop on Research Definitions for Reserve and Resilience in Cognitive Aging and Dementia
Yaakov Stern · Trustees Of Columbia University In The City Of New York
2019–2021 · research · Clinical
Phase 2 Enabling Toxicology Studies of MW151, A Selective Small Molecule Suppressor of Neuroinflammation for Alzheimer’s Disease
Linda Van Eldik · University Of Kentucky (p)
2019–2022 · research · Diagnostics Accelerator
Validation of a rapid non-invasive diagnostic test to predict mild cognitive impairment and early Alzheimer’s disease
Hueseyin Firat · Amoneta Diagnostics
2019–2026 · research · Biomarkers
Targeting Neuroinflammation as a Contributing Pathology in Alzheimer’s Disease Dementia
Val Lowe · Mayo Clinic
2019–2021 · research · Clinical
Development of small molecule activators of glutamate transporter EAAT2 translation for Alzheimer's disease
Chien-Liang Lin · The Ohio State University
2019–2022 · research · Diagnostics Accelerator
Fully automated plasma assays as screening tests for Alzheimer-related amyloid β pathology
Henrik Zetterberg · University of Gothenburg
2019–2025 · research · Diagnostics Accelerator
A non-invasive retinal biomarker as a screening test for Alzheimer’s disease
Peter Van Wijngaarden · Centre for Eye Research Australia
2019–2027 · research · Clinical
Nabilone for Agitation Blinded Intervention Trial (NAB-IT)
Krista Lanctôt · Sunnybrook Research Institute
2019–2024 · research · Clinical
A pilot pharmacodynamic study of Anti-SEMA4D Antibody (VX15) in early Alzheimer’s disease
Eric Siemers · Vaccinex Inc.
2019–2021 · research · Diagnostics Accelerator
Brain-specific tau in blood as an Alzheimer Diagnostic Accelerator
Kaj Blennow · University of Gothenburg
2019–2021 · research · Clinical
ETHERAL : Epigenetic THERapy in ALzheimer’s Disease . A multicenter, multinational, randomized, double-blind, placebo-controlled, 3-arm, 26 weeks parallel-group study to evaluate the safety, tolerability of ORY-2001 in patients with mild-moderate AD
Roger Bullock · Oryzon Genomics S.a.
2019–2026 · research · Clinical
Toward Therapeutic Approaches to TREM2-R47H in Alzheimer’s Disease
Erik Roberson · University of Alabama at Birmingham
2019–2023 · research · Diagnostics Accelerator
Plasma Cell-Free RNA as Alzheimer's Disease non-invasive biomarker
Laura Ibanez · Washington University in St. Louis
2019–2022 · research · Drug Discovery
Novel Benzoxazines for the Treatment of Alzheimer's Disease
Kevin Hodgetts · Laboratory For Drug Discovery In Neurodegeneration (lddn)
2019–2021 · research · Biomarkers
Human PET Imaging Evaluations of the Astroglial L-Glutamate EAAT2 Tracer for Alzheimer’s Disease and Related Dementias
John Gerdes · Rio Pharmaceuticals, Inc.
2019–2026 · research · Diagnostics Accelerator
Remote blood biomarker monitoring in frontotemporal lobar degeneration: Neurofilament Surveillance Project (NSP)
Laura Mitic · Bluefield Project To Cure Ftd
2019–2021 · research · Drug Discovery
In Vivo Characterization of a GABA-A alpha-5 Positive Allosteric Modulator
Sharon Rosenzweig-Lipson · AgeneBio (United States)
2019–2021 · research · Drug Discovery
Preclinical Development of an Antibody Therapeutic and an Imaging Agent Targeting Fibrin-Mediated Neuroinflammation
Edward Spack · Therini Bio
2019–2022 · research · Biomarkers
Alzheimer's Disease Neuroimaging Initiative (ADNI) 3 - Amyloid PET Early Frames Add-on Study
Alessio Travaglia · Foundation For The National Institutes Of Health, Inc.
2019–2021 · research · Prevention
Deep Learning to Unveil Neurological Disorder Patterns and Novel Therapeutics from the Electronic Health Records
Riccardo Miotto · Icahn School of Medicine at Mount Sinai
2019–2021 · research · Diagnostics Accelerator
Delivering novel neuro-retinal biomarkers for the early diagnosis of Alzheimer’s disease
Tom Macgillivray · University of Edinburgh
2019–2022 · research · Diagnostics Accelerator
HBDx-AD: A validated blood-based microRNA diagnostic kit for Alzheimer’s Disease
Bruno Steinkraus · Hummingbird Diagnostics (Germany)
2019 · conference · Conferences/Other
2019 Alzheimer's Disease-Related Dementias (ADRD) Summit
Alison Drone · Foundation For The National Institutes Of Health, Inc.
2018–2024 · research · Clinical
A Phase II Study of the ApoE mimetic peptide drug CN-105 to reduce Postoperative Delirium and Cognitive Dysfunction after Non-Cardiac Surgery in Older Adults and to Block their Underlying Mechanisms
Miles Berger · Duke University
2018–2019 · research · Clinical
Phase 1 Studies and preparation of clinical phase 2 IND of MW150 : Novel Stress Kinase Inhibitor Candidate
Wayne Anderson · Neurokine Therapeutics
2018–2020 · research · Drug Discovery
Activation of microglial cells to promote clearance of amyloid-beta
Michael Parker · St Vincents Institute of Medical Research
2018–2019 · research · Prevention
Evaluating the effectiveness of CognitiveVitality.org on learning about brain health: a randomized, crossover study in the lay public and healthcare professionals
Richard Isaacson · Cornell University
2018–2019 · research · Biomarkers
Resilience Biomarker NPTX2 and AD Progression
Paul Worley · Johns Hopkins University
2018–2021 · research · Clinical
Vascular activation: A novel therapeutic target for Alzheimer's disease
Paula Grammas · University of Rhode Island
2018–2021 · research · Prevention
Building a Brain Health Ecosystem: Improving Detection and Diagnosis Through Healthcare System Change and Consumer Engagement
George Vradenburg · UsAgainstAlzheimer
2018–2019 · research · Drug Discovery
Optimization of selective DYRK1A inhibitors as a treatment for AD
Christopher Hulme · University of Arizona
2018 · conference · Conferences/Other
Alzheimer's Disease Research Summit 2018 Sponsorship
Alison Drone · Foundation For The National Institutes Of Health, Inc.
2018–2020 · prize · Clinical
2018 Annual Goodes Prize for Excellence in Alzheimer’s Drug Discovery: Imaging Sub-study for the HOPE4MCI Phase 3 Trial
Michela Gallagher · AgeneBio (United States)
2018–2020 · research · Clinical
Glutamatergic Dysfunction in Cognitive Aging: Riluzole in Mild Cognitive Impairment - Expansion to an additional clinical site
Ana Pereira · Icahn School of Medicine at Mount Sinai